1 report for “Account attribution”

FDA OCET BAA Overview and Priorities — selected contract metadata, October 25, 2023

Robert Orr, U.S. Food and Drug Administration. fda.gov. October 25, 2023.

The 2023 FDA presentation repeats 75F40120C00176 as an FDA/OMHHE collaboration studying COVID-19 illness in diverse populations. It provides a later official account of the same funding relationship described in 2022, rather than a new independent study or award. Nolan’s connection comes from the separate MaxFuse acknowledgement; no classified UAP access is reported.